IRB #

STUDY00020747

Title

MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer

Principal Investigator

Adel Kardosh

Study Purpose

The purpose of this study is to determine if taking tucatinib with trastuzumab or tucatinib alone will shrink or keep your HER2+ metastatic colorectal cancer from getting worse.

Medical Condition(s)

Colorectal Cancer
Metastatic Colorectal Cancer
HER2 Positive

Eligibility Criteria

Inclusion
-Have confirmed metastatic or unresectable adenocarcinoma of the colon or rectum
-Have confirmed HER2-positive metastatic colorectal cancer
-Progression of unresectable or metastatic colorectal cancer after last therapy

Exclusion
-Have any side effect related to prior cancer therapies that has not resolved
-History of another cancer within 3 years

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

Approximately 5 years

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Seattle Genetics Inc

Recruitment End

12/31/2023

Compensation Provided

No


Go Back